Cannabinoids for the treatment of multiple sclerosis: no smoke without fire?

References

• Devane WA, Dysarz FA, Johnson MR etal Determination and characterization of a cannabinoid receptor in rat brain. Mal Pharmacol 34, 605–613 (1988).
   Google Scholar
• •First paper to report the cannabinoid CB1 receptor.
   Google Scholar
• Herkenham M, Lynn AB, Little MD eta]. Cannabinoid receptor localization in brain. Proc. Nat. Acad. Sci. USA 87, 1932–1936 (1990).
   PubMed Web of Science ®Google Scholar
• Matsuda LA, Lolait SJ, Brownstein MJ etal Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346, 561–564 (1990).
   PubMed Web of Science ®Google Scholar
• Devane WA, Hanus L, Breuer A etal. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 1946–1949 (1992).
   Google Scholar
• Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365, 61–65 (1993).
   Google Scholar
• Piomelli D, Giuffrida A, Calignano A, Rodriguez de Fonseca E The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol Sci. 21, 218–224 (2000).
   PubMed Web of Science ®Google Scholar
• Williamson EM, Evans FJ. Cannabinoids in clinical practice. DITIF 60, 1303–1314 (2000).
   Google Scholar
• Rice AS. Cannabinoids and pain. G117: Opin Invest. Drugs 2,399–414 (2001).
   Google Scholar
• ••Provides a systematic, up-to-date analysisof the literature on the analgesic effects of cannabinoids.
   Google Scholar
• Pertwee RG. Cannabinoid receptors and pain. Prog. Neurobial 63, 569–611 (2001).
   PubMed Web of Science ®Google Scholar
• ••Provides a systematic, up-to-date analysisof the literature on the analgesic effects of cannabinoids.
   Google Scholar
• Hall WD, Degenhardt LJ, Currow D. Allowing the medical use of cannabis. Med Aust. 175, 39–40 (2001).
   Google Scholar
• British Medical Association. Therapeutic Uses of Cannabis. Harwood Academic Publishers, The Netherlands (1997).
   Google Scholar
• Smith PF, Darlington CL. Recent developments in drug therapy for multiple sclerosis. Multiple Sclerosis 5,110–120 (1999).
   PubMedGoogle Scholar
• O'Connor P Key issues in the diagnosis and treatment of multiple sclerosis. Neurolology59, S1—S33 (2002).
   Google Scholar
• Consroe P, Musty R, Rein J, Tillery W, Pertwee R. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neural 38, 44–48 (1997).
   Google Scholar
• Dyer O. Cannabis trial launched in patients with MS. BE Med 322, 192 (2001).
   Google Scholar
• US Institute of Medicine. Marijuana and Medicine. Assessing The Science Base. National Academy of Sciences, USA (1999).
   Google Scholar
• World Health Organization. Programme on substance abuse, cannabis: a Health Pempective Ancl Researrh Agenda. WHO Geneva, Switzerland (1997).
   Google Scholar
• Hall W, Solowij, N. Adverse effects of cannabis. Lancet352, 1611–1616 (1998).
   PubMed Web of Science ®Google Scholar
• IFN-0 Multiple Sclerosis Study Group. Interferon fi-lb is effective in relapsing-remitting multiple sclerosis I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43, 655–661 (1993).
   Google Scholar
• Paty DE, Li DKB, Ubc MS eta], and the MRI Study Group. Interferon-13-lb is effective in relapsing—remitting multiple sclerosis II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43, 662–667 (1993).
   Google Scholar
• Stone LA, Frank JA, Albert PS eta]. The effect of interferon-0 on blood—brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing—remitting multiple sclerosis. Ann. Neuml 37, 611–619 (1995).
   Google Scholar
• Jacobs LD, Cookfair DL, Rudick RA eta]. Intramuscular interferon-p-la for disease progression in relapsing multiple sclerosis. Ann. Neural 39, 285–294 (1996).
   Google Scholar
• Sibley WA. Clinical efficacy of interferon-13- lb in multiple sclerosis — The US/Canadian multicenter trial evidence. Ol17. Immunotherapy5\(Suppl. 1), 41–46 (1996).
   Google Scholar
• Rudick RA, Goodkin DE, Jacobs LD et al Impact of interferon-p-la on neurologic disability in relapsing multiple sclerosis. Neurology 49, 358–363 (1997).
   PubMed Web of Science ®Google Scholar
• Calabresi PA, Stone LA, Bash CN etal Interferon- 13 results in immediate reduction of contrast-enhanced MRI lesions in multiple sclerosis patients followed by weekly MRI. Neurology 48, 1446–1448 (1997).
   PubMed Web of Science ®Google Scholar
• Pozzilli C, Bastianello S, Koudriavtseva T etal Magnetic resonance imaging changes with recombinant human interferon-13-lb — a short-term study in relapsing—remitting multiple sclerosis. j Neural Neurosurg. Psychiat. 61, 251–258 (1996).
   Google Scholar
• Li DKB, Paty DW, Koopman RA et al The effects of interferon-0-lb in multiple sclerosis as assessed by MRI. Clin. hnmunotherapy 5\(Suppl. 1), 47–54 (1996).
   Google Scholar
• Simon JH, Jacobs LD, Campion M etal Magnetic resonance studies of interferon-0- la for relapsing multiple sclerosis. Ann. Neural 43, 79–87 (1998).
   Google Scholar
• Weinstock-Guttman B, Rnshoff RM, Kinkel P et al The interferons: biological effects, mechanisms of action and use in multiple sclerosis. Ann. .Aiuml. 37,7–15 (1995).
   Google Scholar
• Mohr DC, Goodkin DE, Likosky W etal. Treatment of depression improves adherence to interferon-13-lb therapy for multiple sclerosis. Arch. .Ainrol 54, 531–533 (1997).
   Google Scholar
• van Oosten BW, Tragent L, Barkhof F eta]. Multiple sclerosis therapy: a practical guide. Drugs 49, 200–121 (1995).
   PubMedGoogle Scholar
• Petro DJ, Ellenberger C. Treatment of human spasticity with A-9- tetrahydrocannabinol. j Clin. Pharmacol 21, S413—S416 (1981).
   Google Scholar
• Petro DJ. Marihuana as a therapeutic agent for muscle spasm and spasticity. fiychosomatics21, 81–85 (1980).
   PubMed Web of Science ®Google Scholar
• ••One of the earliest studies of the effects of cannabis on MS.
   Google Scholar
• Ungerleider jT, Andrysiak T, Fairbanks L, Bison GW, Myers, L.W. 4-9-tetrahydrocannabinol in the treatment of spasticity associated with multiple sclerosis. Adv Alcoholism Substance Abuse7, 39–50 (1988).
   Google Scholar
• ••One of the earliest studies of the effects ofcannabis on MS.
   Google Scholar
• Greenberg HS, Werness SAS, Pugh, JE, Andrus RO, Anderson DJ, Domino EA. Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers. Clin. Pharmacol Therap. 55,324–328 (1994).
   Google Scholar
• ••One of the earliest studies of the effects ofcannabis on MS.
   Google Scholar
• Clifford D. Tetrahydrocannabinol for tremors in multiple sclerosis. Anna'. Neural 13,669–671 (1983).
   PubMed Web of Science ®Google Scholar
• Dell'Osso L. Suppression of pendular nystagmus by smoking cannabis in a patient with multiple sclerosis. Neurology 54,2190–2193 (2000)
   PubMed Web of Science ®Google Scholar
• Schon F, Hart PE, Hodgson Thetal Suppression of pendular nystagrnus by smoking cannabis in a patient with multiple sclerosis. Ailtrology53, 2209–2211 (1999).
   Google Scholar
• Killestein J, Hoogervorst ELJ, Reif M et al Safety, tolerability and efficacy of orally administered cannabinoids in MS. Neurology58, 1404–1407 (2002). I argest published clinical trial of the effects of cannabinoids on spasticity in MS.
   Google Scholar
• Meinck H eta Effects of cannabinoids on spasticity and ataxia in multiple sclerosis. j Neural. 226,120–122 (1989).
   Google Scholar
• Martyn C et al Nabilone in the treatment of multiple sclerosis. Lancet345, 579 (1995).
   Google Scholar
• Baker D eta]. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 404,84–87 (2000).
   Google Scholar
• •Evidence that cannabinoids also inhibit spasticity in an animal model of MS.
   Google Scholar
• Berrendero F, Sanchez A, Cabranes A eta]. Changes in cannabinoid (CB1) receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosis. Synapse 41,195–202 (2001).
   Google Scholar
• Achiron A etal Dexanabinol (HU-211) effect on experimental autoimmune encephalomyelitis: implications for the treatment of acute relapses of multiple sclerosis. J. Neuroimmunal 102,26–31 (2000).
   Google Scholar
• Baker D, Pryce G, Croxford JL eta]. Endocannabinoids control spasticity in a multiple sclerosis model. FASEBJ 15, 300–302 (2001).
   Google Scholar
• Welch SP, Dunlow LD, Patrick GS Razdan RK. Characterization of anandamide- and fluoroanandamide-induced antinociception and crosstolerance to delta-9-tetrahydrocannabinol after it: administration to mice: blockade of delta-9-tetrahydrocannabinol-induced antinociception. j Pharmacol. Exp. Therap. 273,1235-1244 (1995).
   Google Scholar
• Calignano A, La Rana G, Giuffrida A, Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature 394, 277–281 (1998).
   PubMed Web of Science ®Google Scholar
• Elphick MR, Egertova M. The neurobiology and evolution of cannabinoid signalling. Philos. Trans. Royal Soc. Land — Series B: Biol. Sci. 356,381-408 (2001).
   Google Scholar
• Kreitzer AC, Regehr, W.G. Retrograde signalling by endocannabinoids. G117: Opin. Neurobial 12,324–330 (2002).
   Google Scholar
• Alger BE. Retrograde signalling in the regulation of synaptic transmission: focus on endocannabinoids. Frog: Neumbial 68, 247–286 (2002).
   Google Scholar
• Campbell FA, Tramer MR, Caroll D, Reynolds DJ, Moore RA, McQuay HJ. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BE Med 323,13–16 (2001).
   PubMed Web of Science ®Google Scholar
• Tramer MR, Caroll D, Campbell FA etal Cannabinoids for control of chemotherapy-induced nausea and vomiting: quantitative systematic review. BE Med. J. 323,16–21 (2001).
   PubMed Web of Science ®Google Scholar
• Voth EA, Schwartz RII. Medicinal applications of 4-9-tetrahydrocannabinol. Ann. Int. Med. 126,791-798 (1997).
   Google Scholar
• Deas D, Gerding L, Hazy J. Marijuana and panic disorder. jAm. Acad. Child Adolesc. fiychiat. 39,1467 (2000).
   PubMedGoogle Scholar
• Taylor HG. Analysis of the medical use of marijuana and its societal implications. J. Am. Pharmaceut. Assoc. 38,220–227 (1998).
   Google Scholar
• Thomas H. A community survey of adverse effects of cannabis use. Drug Alcohol. Depend. 42,201–207 (1996).
   PubMedGoogle Scholar
• Patel S, Hillard CJ. Cannabinoid CB1 receptor agonists produce cerebellar dysfunction in mice. J. Phatmacol Exp. Therap. 297,629-637 (2001).
   Google Scholar
• Newsham-West D eta Potent effects of a selective cannabinoid receptor agonist on some medial vestibular nucleus neurons. Eur I Pharmacol 348, R1—R2 (1998).
   Google Scholar
• Di Marzo V, Berrendero F, Bisogno T etal Enhancement of anandamide formation in the limbic forebrain and reduction of endocannabinoid contents in the striatum of 4-9-tetrahydrocannabinol-tolerant rats. I Neurochem. 74,1627–1635 (2000).
   PubMed Web of Science ®Google Scholar
• Haney M, Ward AS, Comer SD etal Abstinence symptoms following oral THC administration in humans. Psychopharmacol 141,385–494 (1999).
   PubMed Web of Science ®Google Scholar
• Haney M, Ward AS, Comer SD etal Abstinence symptoms following smokedmarijuana in humans. Psychopharmacol 141,395–404 (1999).
   PubMed Web of Science ®Google Scholar
• Coutts AA, Anavi-Goffer S, Ross RA etal Agonist-induced internalization and trafficking of cannabinoid CB1 receptors in hippocampal neurons. J. Neurosci., 21, 2425–2433 (2001).
   Google Scholar
• Tanda G, Munzar P, Goldberg SR. Self- administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys. Nature Neurosci. 3, 1073–1074 (2000).
   Google Scholar
• Tanda G, Pontieri FE, Dichiara G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu-1 opioid receptor mechanism. Science 276,2048-2050 (1997).
   Google Scholar
• McKallip RJ, Lombard C, Martin BR etal A- 9-THC-induced apoptosis in the thymus and spleen as a mechanism of immunosuppresion in rdtmand in Ova./ Phatmacol Exp. ?hemp. 302,451-465 (2002). Website
   Google Scholar
• www.gwpharm.cominews pres_05_nov_02.html (Accessed March 2003)
   Google Scholar
• •GW Pharmaceuticals website describing the results of their latest Phase III clinical trials. Affiliation
   Google Scholar